Exeliom Biosciences Company Profile

Background

Exeliom Biosciences, established in 2016 in Paris and Dijon, France, is a clinical-stage biopharmaceutical company specializing in microbiome-based immunotherapies. The company's mission is to innovate treatments for inflammatory bowel diseases, cancer, and infectious diseases by leveraging the immunomodulatory properties of specific gut microbiota. Their lead candidate, EXL01, is an oral biotherapeutic derived from Faecalibacterium prausnitzii, a dominant commensal bacterium known for its significant role in gut health and immune regulation.

Key Strategic Focus

Exeliom Biosciences focuses on developing immunotherapies that harness the microbiome's potential to modulate the immune system. Their primary objective is to advance EXL01 through clinical trials targeting conditions such as Crohn's disease, various cancers, and recurrent Clostridium difficile infections. By integrating EXL01 with standard-of-care treatments, particularly immune checkpoint inhibitors, the company aims to enhance therapeutic efficacy and patient outcomes.

Financials and Funding

Since its inception, Exeliom Biosciences has secured a total of €24 million ($26 million) in Series A funding. The funding timeline includes:

2018: Initial closing of €7 million.

2021: First extension of €3 million.

2023: Final extension of €8 million, led by CE-Ventures, the corporate venture capital platform of Crescent Enterprises.

Additional investors include Auriga Partners, UI Investissement, Capital Grand Est, and Biocodex. The capital is allocated to progressing clinical development of EXL01 in immuno-oncology and infectious diseases.

Pipeline Development

Exeliom Biosciences' pipeline centers on EXL01, with several clinical trials underway:

Crohn's Disease: A Phase 1 study (MAINTAIN) evaluating EXL01 for maintaining remission in adults with mild to moderate Crohn's disease.

Immuno-Oncology: Planned Phase 1/2 trials combining EXL01 with immune checkpoint inhibitors in:

Gastric cancer.

Non-small cell lung cancer (NSCLC).

Hepatocellular carcinoma (HCC).

Infectious Diseases: A Phase 1/2 study assessing EXL01 as an alternative to fecal transplantation for recurrent C. difficile infection.

Technological Platform and Innovation

Exeliom Biosciences distinguishes itself through its proprietary development of EXL01, a single-strain live biotherapeutic product derived from F. prausnitzii. This bacterium exhibits unique immunomodulatory properties, particularly through the activation of NOD2 receptors in macrophages, leading to metabolic reprogramming of immune cells. This mechanism underpins EXL01's potential across various therapeutic areas, including inflammatory bowel diseases, oncology, and infectious diseases.

Leadership Team

Benjamin Hadida: Co-founder and Chief Executive Officer.

Prof. Harry Sokol: Co-founder and acting Chief Medical Officer; Professor of Gastroenterology at Saint Antoine Hospital in Paris.

Dr. Philippe Langella: Co-founder; Research Director at INRAe.

Prof. Patrick Gervais: Co-founder; Professor of Process Engineering at AgroSup Dijon.

These founders have been instrumental in identifying and harnessing the therapeutic potential of F. prausnitzii.

Competitor Profile

Market Insights and Dynamics

The human microbiome market is projected to grow from $600 million in 2021 to $3.1 billion by 2029, reflecting a compound annual growth rate (CAGR) of 23%. This growth is driven by increasing recognition of the microbiome's role in health and disease, leading to heightened investment and research in microbiome-based therapies.

Competitor Analysis

Key competitors in the microbiome-based therapeutics space include:

Seres Therapeutics: Focuses on developing microbiome therapeutics for infectious diseases and immune-mediated conditions.

Vedanta Biosciences: Develops defined bacterial consortia for treating autoimmune and inflammatory diseases.

Rebiotix (a Ferring Company): Specializes in microbiota restoration therapies for recurrent C. difficile infection.

These companies, like Exeliom Biosciences, are advancing microbiome-based therapies, each with unique approaches and therapeutic targets.

Strategic Collaborations and Partnerships

Exeliom Biosciences has established strategic partnerships to bolster its research and development efforts:

CE-Ventures: Led the final extension of the Series A funding round, providing financial support and strategic guidance.

Biocodex: An independent multinational pharmaceutical company investing in Exeliom's development programs.

These collaborations enhance Exeliom's capacity to advance its clinical programs and expand its therapeutic pipeline.

Operational Insights

Exeliom Biosciences differentiates itself through its focus on single-strain live biotherapeutics, particularly the development of EXL01 derived from F. prausnitzii. This targeted approach allows for precise modulation of the immune system, potentially leading to improved efficacy and safety profiles compared to broader microbiome-based therapies. The company's lean operational model, combined with strategic partnerships, positions it to efficiently navigate the competitive landscape of microbiome therapeutics.

Strategic Opportunities and Future Directions

Looking ahead, Exeliom Biosciences aims to:

Advance Clinical Programs: Progress EXL01 through ongoing and planned Phase 1/2 trials in Crohn's disease, various cancers, and C. difficile infection.

Expand Therapeutic Applications: Explore additional indications where EXL01's immunomodulatory properties may be beneficial.

Strengthen Partnerships: Seek collaborations with pharmaceutical companies to enhance development and commercialization efforts.

Secure Additional Funding: Attract further investment to support late-stage clinical trials and regulatory submissions.

By leveraging its scientific expertise and strategic partnerships, Exeliom Biosciences is well-positioned to bring innovative microbiome-based therapies to market, addressing unmet needs in immunology and infectious diseases.